Zymeworks hosts R&D day highlighting continued clinical progress

Zymeworks (ZYME) announced highlights from its R&D Day reviewing the Company’s development progress on its wholly-owned pipeline assets and expansion into new therapeutic areas in hematological cancers and autoimmune and inflammatory diseases. Company on track to deliver five Investigational New Drug applications as part of ‘5 by 5’ solid tumor strategy 18 months ahead of original target; Nomination of ZW209, a novel trispecific T cell engager, as fifth development candidate in the Company’s solid tumor portfolio; Expansion into autoimmune and inflammatory diseases and hematology oncology leverages the Company’s clinically validated Azymetric technology platform and expertise in multispecific therapeutics; ZW1528, the Company’s first development candidate in AIID, demonstrates dual blockade of two complementary pathways of respiratory inflammation and offers potential benefit in mixed-type chronic obstructive pulmonary disease